TAS 115

Drug Profile

TAS 115

Alternative Names: Dual MET/VEGFR inhibitor - Taiho Pharmaceutical; TAS-115

Latest Information Update: 13 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Taiho Pharmaceutical
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Hepatocyte growth factor inhibitors; Proto oncogene protein c met inhibitors; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Prostate cancer
  • Phase I Solid tumours

Most Recent Events

  • 08 Sep 2017 Interim adverse events and efficacy data from a phase I trial in Prostate cancer presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
  • 02 Dec 2016 Taiho Pharmaceutical plans a phase II trial for Prostate cancer in Japan (JapicCTI-163448)
  • 01 Nov 2016 Phase-II clinical trials in Prostate cancer in Japan (PO) (JapicCTI-163448)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top